Acadia Pharmaceuticals Presents DAYBUE Real-World Evidence And Additional Data In Rett Syndrome At The 2024 IRSF Annual Scientific Meeting
Acadia Pharmaceuticals Presents DAYBUE Real-World Evidence And Additional Data In Rett Syndrome At The 2024 IRSF Annual Scientific Meeting
阿卡迪亚制药在2024年IRSF年会上展示霞症的DAYBUE实际证据和其他数据
Acadia Pharmaceuticals, Inc. (NASDAQ:ACAD) today announced that interim data from the open-label real-world LOTUS study will be presented at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting, being held this week in Westminster, Colorado. LOTUS is an ongoing, caregiver-reported study evaluating the efficacy and tolerability outcomes in patients with Rett syndrome treated with DAYBUE (trofinetide).
Acadia Pharmaceuticals公司（纳斯达克股票代码：ACAD）今天宣布，开放标签真实世界LOTUS研究的中期数据将在本周举行的2024年国际Rett综合征基金会（IRSF）年度科学会议上展示，地点在科罗拉多州威斯敏斯特市。LOTUS是一项正在进行中、以护理者报告为基础，评估Rett综合征患者使用DAYBUE（trofinetide）治疗的有效性和耐受性结果的研究。